Avalyn Pharma adds Robert Meyer, M.D. to board of directors
The former FDA official and regulatory consultant joins as a Class II director effective September 15, 2026.
SEC filing
Latest
2 stories
Wednesday, September 16
Wednesday, August 12
Avalyn completes enrollment in Phase 2b pulmonary fibrosis trial of AP01
The company reported topline data expected in the second half of 2027 and cash runway into 2029 as of its second-quarter 2026 results.
SEC filing